ABSTRACT
Background Since 1920, a decrease in serum cholesterol has been identified as a marker of severe pneumonia. We have assessed the performance of serum apolipoprotein-A1, the main transporter of HDL-cholesterol, to identify the early spread of coronavirus disease 2019 (Covid-19) in the general population and its diagnostic performance for the Covid-19.
Methods We compared the daily mean serum apolipoprotein-A1 during the first 30 weeks of 2020 in a population that is routinely followed for a risk of liver fibrosis risk in the USA (183,112 sera) and in France (18,316 sera) in relation to a local increase in confirmed cases, and in comparison to the same period in 2019 (respectively 234,881 and 26,056 sera). We prospectively assessed the sensitivity of this marker in an observational study of 136 consecutive hospitalized cases and retrospectively evaluated its specificity in 7,481 controls representing the general population.
Results The mean serum apolipoprotein-A1 levels in these populations began decreasing in January 2020, compared to the same 30 weeks in 2019. This decrease was highly correlated to and in parallel with the daily increase in confirmed Covid-19 cases in the following 30 weeks, in both France and USA, including the June and mid-July recovery periods in France. Apolipoprotein-A1 at the 1.25 g/L cutoff had a sensitivity of 90.6% (95%CI84.2-95.1) and a specificity of 96.1% (95.7-96.6%) for the diagnosis of Covid-19. The area under the characteristics curve was 0.978 (0.957-0.988), and outperformed haptoglobin and liver function tests. The adjusted risk ratio for survival without transfer to intensive care unit was 5.61 (95%CI 1.02-31.0;P=0.04).
Conclusion Apolipoprotein-A1 could be both a sentinel of the pandemic in existing routine surveillance of the general population with no new blood sample, as well as a candidate predictor of suspected Covid-19 in multivariate analysis in cases with a negative virological test. NCT01927133, CER-2020-14.
Question Does serum apolipoprotein-A1 decrease could be a very early biomarker of SARS-CoV-2 pandemic?
Findings During the 30 weeks of 2020 we observed in two large cohorts of patients at risk of liver fibrosis a highly significant decrease of serum apolipoprotein-A1, not observed in previous years. This decrease was highly correlated to and in parallel with the daily increase in confirmed Covid-19 cases, including the recovery period.
Meaning Apolipoprotein-A1 could be used as a sentinel of the pandemic in existing routine surveillance of the general population.
Competing Interest Statement
I have a potential conflict of interest as the inventor of FibroTest, and founder of BioPredictive a spinoff company of Sorbonne University. The patent belongs to the French public organization Assistance Publique Hopitaux de Paris. Olivier Deckmyn, Jean Marie Castille, Fabienne Drane, Yen Ngo, Clemence Franc, are full employee of BioPredictive
Clinical Trial
NCT01927133, CER-2020-14
Funding Statement
This project was funded by the European Grant EIT health ProCoP 20879, Patrice Cacoub being the awarded author.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The prospective observational study in Covid-19 patients was approved by CER-Sorbonne University IRB, 2020CER202014, with a signed informed consent. Clinical investigation was conducted according to the principles of the Declaration of Helsinki. All authors had access to the study data and reviewed and approved the final manuscript. The components of Fibrotest and Nash-FibroTest were measured in routine in all patients with a risk of liver disease in France. The different databases integrated were used on sera anonymously. All the retrospective database analyses previously published either non-interventional study, without supplementary blood sample, were exempt from institutional review board (IRB) review (ethical committee of Comite de Protection des Personnes of Paris, Ile-de-France FIBROFRANCE project. CPPIDFVI, 101996DR964, DR2012222 and USA NCT01927133).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are fully available from the supplementary files.
